Hypera Sa S/Adr (HYPMY) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen. Welcome to Hypera Pharma's earnings call for the second quarter of 2026. We have with us Mr. Breno Oliveira, CEO, and Mr. Ramon Sanches, CFO and Investor Relations Officer. This event is being recorded and may be watched on the company's investor relations website at ri.epera.com.br. All participants will be in listen-only mode during the company's presentation. After that, we will begin the question and answer session when further instructions will be given. Before proceeding, we would like to remind you that some of the information contained in this conference call may include forward looking statements or expectations about future events. This information is subject to known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. I will now turn it over to Mr. Breno Oliveira, who will begin the company's presentation. Go ahead, sir. Good morning, everyone. It's a pleasure to welcome you to our earnings conference call for the second quarter of 2026. I'll begin the presentation on slide three. This quarter, we combined growth in sell-out, revenue, EBITDA and net income with strong operating cash flow and reduction in net debt. Our net revenue grew 8.5%, driven primarily by 7.6% growth in sell-out. The sellout growth was primarily driven by progress in the skincare, central nervous system, and gut health categories, where the company stands out with a broad portfolio of products, including those commonly used during GLP-1-based treatments. New product launches over the past 12 months once again contributed to our performance, adding 2.2 percentage points to sellout growth this quarter. As a result, we gained market share in our target markets, which grew by 6.2% in th...